Clinical and Experimental Pediatrics

대한소아청소년과학회 (The Korean Pediatric Society)
권호 표지
DOI QR코드

DOI QR Code

Philadelphia chromosome-positive acute lympho-blastic leukemia in childhood

  • Koo, Hong-Hoe (Department of Pediatrics, Samsung Medical Center Sungkyunkwan University School of Medicine)
  • 투고 : 2011.02.14
  • 심사 : 2011.03.07
  • 발행 : 2011.03.15
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

In pediatric patients with acute lymphoblastic leukemia (ALL), the Philadelphia chromosome translocation is uncommon, with a frequency of less than 5%. However, it is classified as a high or very high risk, and only 20-30% of Philadelphia chromosome-positive (Ph+) children with ALL are cured with chemotherapy alone. Allogeneic hematopoietic stem cell transplantation from a closely matched donor cures 60% of patients in first complete remission. Recent data suggest that chemotherapy plus tyrosine kinase inhibitors (TKIs) may be the initial treatment of choice for Ph+ ALL in children. However, longer observation is required to determine whether long-term outcome with intensive imatinib and chemotherapy is indeed equivalent to that with allogeneic related or alternative donor hematopoietic stem cell transplantation (HSCT). Reports on the use of second-generation TKIs in children with Ph+ ALL are limited. A few case reports have indicated the feasibility and clinical benefit of using dasatinib as salvage therapy enabling HSCT. However, more extensive data from clinical trials are needed to determine whether the administration of second-generation TKIs in children is comparable to that in adults. Because Ph+ ALL is rare in children, the question of whether HSCT could be a dispensable part of their therapy may not be answered for some time. An international multicenter study is needed to answer the question of whether imatinib plus chemotherapy could replace sibling allogeneic HSCT in children with Ph+ ALL.

키워드

참고문헌

  1. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006;354:166-78. https://doi.org/10.1056/NEJMra052603
  2. Schlieben S, Borkhardt A, Reinisch I, Ritterbach J, Janssen JW, Ratei R, et al. Incidence and clinical outcome of children with BCR/ABL-positive acute lymphoblastic leukemia (ALL). A prospective RT-PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials ALL-BFM-90 and CoALL-05-92. Leukemia 1996;10:957-63.
  3. Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood 1996;88:2375-84.
  4. Lee HJ, Thompson JE, Wang ES, Wetzier M. Philadelphia chromosomepositive acute lymphoblastic leukemia: current treatment and future perspective. Cancer 2011;117:1583-94. https://doi.org/10.1002/cncr.25690
  5. Fielding AK, Rowe JM, Richards SM, Buck G, Moorman AV, Durrant IJ, et al. Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the international ALL Trial MRC UKALLXII/ECOG2993. Blood 2009;113:4489-96. https://doi.org/10.1182/blood-2009-01-199380
  6. Arico M, Valsecchi MG, Camitta B, Schrappe M, Chessells J, Baruchel A , et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 2000;342:998-1006. https://doi.org/10.1056/NEJM200004063421402
  7. Arico M, Schrappe M, Hunger SP, Carroll WL, Conter V, Galimberti S, et al. Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005. J Clin Oncol 2010;28:4755-61. https://doi.org/10.1200/JCO.2010.30.1325
  8. Druker BJ, Tamura S, Buchdunger E, Ohno S, Seqal GM, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561-6. https://doi.org/10.1038/nm0596-561
  9. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038-42. https://doi.org/10.1056/NEJM200104053441402
  10. Champagne MA, Capdeville R, Krailo M, Peng B, Rosamilia M, Therrien M, et al. Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study. Blood 2004;104:2655-60. https://doi.org/10.1182/blood-2003-09-3032
  11. Schultz KR, Bowman WP, Aledo A, Slayton WB, Sather H, Devidas M, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. J Clin Oncol 2009;27:5175-81. https://doi.org/10.1200/JCO.2008.21.2514
  12. Fielding AK. Current treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Haematologica 2010;95:8-12. https://doi.org/10.3324/haematol.2009.015974
  13. Huang WS, Metcalf CA, Sundaramoorthi R, Wang Y, Zou D, Thomas RM, et al. Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl) ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl) phenyl}benzamide(AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant. J Med Chem 2010;53:4701-19. https://doi.org/10.1021/jm100395q
  14. O'Hare T, Walters DK, Stoffregen EP, Jia T, Manley PW, Mestan J, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005;65:4500-5. https://doi.org/10.1158/0008-5472.CAN-05-0259
  15. Porkka K, Koskenvesa P, Lundan T, Rimpilainen J, Mustjoki S, Smykla R, et al. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosomepositive leukemia. Blood 2008;112:1005-12. https://doi.org/10.1182/blood-2008-02-140665
  16. Schultz KR, Prestidge T, Camitta B. Philadelphia chromosome-positive Acute Lymphoblastic Leukemia in Children: New and Emerging Treatment Options. Expert Rev Hematol 2010;3:731-42. https://doi.org/10.1586/ehm.10.60
  17. Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, Ray A, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005;7:129-41. https://doi.org/10.1016/j.ccr.2005.01.007
  18. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome positive ALL. N Engl J Med 2006;354:2542-51. https://doi.org/10.1056/NEJMoa055104
  19. Ottmann OG, Larson RA, Kantarjian HM, Coutre PI, Baccarani M, Haque A, et al. Nilotinib in patients with relapsed/refractory Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) who are resistant or intolerant to imatinib. Blood 2007;110:2815a.
  20. Schmid H, Jaeger BA, Lohse J, Suttorp M. Longitudinal growth retardation in a prepubertal girl with chronic myeloid leukemia on long-term treatment with imatinib. Haematologica 2009;94:1177-9. https://doi.org/10.3324/haematol.2009.008359
  21. Vandyke K, Dewar AL, Fitter S, Menicanin D, To LB, Hughes TP, et al. Imatinib mesylate causes growth plate closure in vivo. Leukemia 2009;23:2155-9. https://doi.org/10.1038/leu.2009.150
  22. Pane F, Cimino G, Izzo B, Camera A, Vitale A, Quintarelli C, et al. Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia. Leukemia 2005;19: 628-35. https://doi.org/10.1038/sj.leu.2403683
  23. Yanada M, Takeuchi J, Sugiura I, Akiyama H, Usui N, Yagasaki F, et al. Karyotype at diagnosis is the major prognostic factor predicting relapse free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy. Haematologica 2008;93:287-90. https://doi.org/10.3324/haematol.11891
  24. Carroll AJ, Heerema NA, Devidas M, Bowman WP, Wang C, Trigg M, et al. Secondary chromosomal abnormalities appear to be less prognostic for children with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) treated with intensified Imatinib and chemotherapy: Results of the Children's Oncology Group (COG) study AALL0031. Blood 2009;114:2606a. https://doi.org/10.1182/blood-2009-03-208355

피인용 문헌

  1. Potential of ponatinib to treat chronic myeloid leukemia and acute lymphoblastic leukemia vol.6, pp.None, 2011, https://doi.org/10.2147/ott.s36980
  2. Hematopoietic stem cell transplant versus chemotherapy plus tyrosine kinase inhibitor in the treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL) vol.6, pp.1, 2011, https://doi.org/10.1016/j.hemonc.2013.03.001
  3. Leukemia in Children : Getting Back to School—Part 1 vol.30, pp.2, 2015, https://doi.org/10.1177/1942602x15570256
  4. Adolescent and young adult patients with cancer: a milieu of unique features vol.12, pp.8, 2011, https://doi.org/10.1038/nrclinonc.2015.92
  5. Impact of tyrosine kinase inhibitors on the statural growth in children with acute lymphoblastic leukemia vol.95, pp.None, 2011, https://doi.org/10.1016/j.leukres.2020.106405
  6. Acute lymphoid leukemia etiopathogenesis vol.48, pp.1, 2021, https://doi.org/10.1007/s11033-020-06073-3
  7. Genomic Analyses of Pediatric Acute Lymphoblastic Leukemia Ph+ and Ph-Like-Recent Progress in Treatment vol.22, pp.12, 2011, https://doi.org/10.3390/ijms22126411
  8. Advances in Electrochemical and Acoustic Aptamer-Based Biosensors and Immunosensors in Diagnostics of Leukemia vol.11, pp.6, 2021, https://doi.org/10.3390/bios11060177